Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    Home»BioTech»China Medical System’s MSCI-ESG Rating Upgraded to “AA”, Reaching the Global Leading Level
    BioTech

    China Medical System’s MSCI-ESG Rating Upgraded to “AA”, Reaching the Global Leading Level

    Marie JonesBy Marie JonesDecember 22, 2020No Comments2 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    On December 17, the largest index provider, Morgan Stanley Capital International (MSCI) updated a report on the ESG (Environmental, Social and Governance) rating for China Medical System Holdings Limited, a well-established, innovation-driven specialty pharma with a focus on sales & marketing in China. According to the report, China Medical System’s ESG rating has been upgraded from “BBB” to “AA”, surpassing 88% of companies in the global pharmaceutical industry, and symbolizing that the Company has reached a leading level among its global peers in ESG management.

    In the report, MSCI recognized China Medical System’s outstanding performance in Corporate Governance, Corporate Behavior, Product Safety and Quality, Human Capital Development and Access to Health Care, and commented: “Leads peers in business ethics and talent management practices”. MSCI also gave a positive assessment of the Company’s Corporate Behavior, “China Medical System has evidence of detailed policies on business ethics and corruption”.

    There are seven levels of the MSCI-ESG rating, from the highest to the lowest are: AAA, AA, A, BBB, BB, B and CCC. Among them, companies with AA or AAA ratings are considered to be industry leaders in managing the most significant ESG risks and opportunities.

    This year, China Medical System’s MSCI-ESG rating has been upgraded by three levels, from “BB” to “AA”.

    According to the Company, “Receiving the ‘AA’ ESG rating from MSCI reflected China Medical System’s long-term focus and resource investment on ESG management and information disclosure, and affirmed the Company’s compliance focus and solid business practices. In recent years, under the leadership of the Board of Directors, the Company’s ESG-related policies are increasingly improved, ESG practices are more standardized, and ESG management is constantly refined. In the future, through self-challenge and transcendence, China Medical System will continuously pursue higher corporate governance goals. The Company will continuously regard innovation as its driving force, to fulfill the unmet medical needs, and contribute to the integrated development of society, the environment, and civilization!”

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleKey Takeaways from Institutional Experts in Preparation for Digital Assets Trends in 2021
    Next Article Philippines: Bloomberry adds P20B to existing loan facility

    Related Posts

    Two Former Moderna Cancer Vaccine Scientists Join Everest Medicines, Accelerating Global Development of Its mRNA Platform

    October 9, 2026

    Micot’s XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal Disease

    October 5, 2026

    Everest Medicines Announces the Acceptance and Priority Review of VELSIPITY(R) Manufacturing Localization Application by the Center for Drug Evaluation of China’s NMPA, Driving Continued Commercial Momentum

    October 2, 2026
    Add A Comment

    Comments are closed.

    Latest News

    • Chervon Names Charlie Harte Director of Field Sales & Recruiting – Canada
    • Chervon Names Thomas G. Kentouris Vice President of Field Sales
    • Chervon Names Randall Durkan Vice President of Supply Chain – North America
    • Indonesia Urges Greater Transparency in Cross-Border Copyright Royalty Governance Before 35 Countries
    • Changzhou Microintelligence Co., Ltd passes HKEX Listing Committee hearing
    • CICC Initiates Coverage of Modern Dental Group (03600.HK) with Outperform Rating and Target Price of HK$10.0: Accelerating Global Expansion with Digital Efficiency
    • Miami Fashion Week(R) Celebrates 10 Years With a Landmark Anniversary Edition, October 13-18, 2026
    • Fullerton and SGX Group open second Value-Up Singapore Equities Challenge to the public with new Open Category
    • Two Former Moderna Cancer Vaccine Scientists Join Everest Medicines, Accelerating Global Development of Its mRNA Platform
    • TMX Group Equity Financing Statistics – September 2026
    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.